Table 1.
DMTs for the treatment of MS*
| Treatment (alphabetic order) | Indication | Route of administration | Dosing/interval |
|---|---|---|---|
| Alemtuzumab (Lemtrada®) | RRMS | i.v. | 5 × 12 mg (1st year) and 3 × 12 mg (2nd year)/short pulsed treatment periods |
| Cladribine (Mavenclad®) | RRMS | p.o. | 3.5 mg/kg (1.75 mg/kg per year) body weight over 2 years/short pulsed treatment periods |
| Dimethyl fumarate (Tecfidera®) | RRMS | p.o. | Maintenance dose 240 mg bid |
| Fingolimod (Gilenya®) | RRMS | p.o. | 0.5 mg/day (in adults) |
| Natalizumab (Tysabri®) | RRMS | i.v. | 300 mg/month, off-label: extended interval dosing (EID) [14]: 300 mg/every 6–8 weeks |
| Ocrelizumab (Ocrevus®) | RRMS, PPMS | i.v. | Induction 300 mg at day 0 and 14; maintenance dose 600 mg/every 6 months |
| Rituximab (off-label) (MabThera®, Truxima®, Rixathon®) | RRMS | i.v. | Induction and maintenance dose variable, mostly 500 mg/every 6 months |
| Siponimod (Mayzent®) | RRMS (FDA), active SPMS (CHMP vote [7]) | p.o. | Maintenance dose dependent on the CYP2C9 genotype: 2mg/day, or 1mg/day, or contraindicated |
| Teriflunomide (Aubagio®) | RRMS | p.o. | 14 mg/day |
*Injectables (interferon beta and glatiramer acetate) without immunosuppressive potential not listed